With Lava Therapeutics still smoldering from the decision to dump its lead blood cancer drug, the biotech is now laying off ...

For the last six weeks, the shadow of potential layoffs has hung over Repare Therapeutics’ employees. Monday, staff learned ...

Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well ...

BioCity Biopharma’s selective endothelin receptor type A (ETA) antagonist has reduced excess proteins in the urine of ...

As Alcon Research seeks to block investee Aurion Biotech from listing on the New York Stock Exchange, another investor has ...

Researchers studying a deadly virus discovered a key protein behind its lethality and successfully used antibodies to ...

Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...

Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...

After leaving the FDA, where she served as director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., ...

After hundreds of FDA employees were suddenly laid off last weekend, including dozens at the agency’s device center, the ...

OrganOx, with its system for actively preserving viable donor tissue ahead of a transplant procedure, has raised $142 million ...

In a recent interview with Fierce Biotech's Chris Hayden, Fortrea's Chief Technology and Data Officer Alaric Jackson ...